Literature DB >> 19353837

Gliomatosis cerebri: clinicopathologic study of 33 cases and comparison of mass forming and diffuse types.

S Park1, Y-L Suh, D-H Nam, S T Kim.   

Abstract

OBJECTIVE: Gliomatosis cerebri (GC) is defined as a diffuse neoplastic glial cell infiltration of the brain with the preservation of anatomical architecture and the sparing of neurons and can be classified into Type 1 (diffuse) and Type 2 (mass forming) GCs macroscopically. There is little information on subtypes of GC. The aim of this study was to evaluate the clinicopathologic findings of GCs and to compare the clinicopathologic findings between Type 1 and Type 2 GCs. MATERIAL: A total of 33 cases of GC were obtained from pathology file of Samsung Medical Center. The diagnosis was based on magnetic resonance imaging findings and histological confirmation for all patients. Fifteen cases were classified into Type 1 and 18 were Type 2 based on the MR images.
METHODS: Clinical information included patients' age, sex, tumor extent, treatment modality and survival. Pathologic features included the amount of rod cells and cytologic anaplasia such as multinucleated tumor giant cells, endothelial cell proliferation, or mitosis. Immunohistochemical study was performed for GFAP, O1, Gal-C, Ki-67, and p53. Clinicopathologic comparison between subtypes and statistical analysis were performed.
RESULTS: Median age at diagnosis was older (56 years) in Type 1 than in Type 2 (44 years). Male to female ratio was about 1.54:1. Mean survival time was shorter (21 months) in Type 2 than in Type 1 GCs (24 months) (p = 0.0447). Histologically, 33 cases of GC were classified into two histologic grades (low and high grade) by cytologic anaplasia. High-grade GC was more common in Type 2 than Type 1 (p = 0.027). Immunohistochemical results demonstrated that the infiltrating tumor cells were undifferentiated cells with astrocytic or oligodendroglial differentiation. Ki-67 labeling index was correlated with subtypes (p = 0.0096). Pathologic features were not correlated with survival.
CONCLUSIONS: Type 1 and 2 GCs are somewhat different in clinical presentation and pathologic features. The age group, survival time, histologic grade, and Ki-67 labeling index were significantly correlated with subtypes ofGCs. Type 2 GC was correlated with poor survival but histologic grade was not.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19353837     DOI: 10.5414/npp28073

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  6 in total

1.  Gliomatosis cerebri presenting as a recurrent cervical myelopathy.

Authors:  Marco A Lima; João C Campos; Bruno L Pessoa; Péricles Maranhão-Filho; Gabriela A Lima; Andreia S Barbosa; Hélio F Lopes
Journal:  J Neurol       Date:  2010-10-06       Impact factor: 4.849

2.  Gliomatosis cerebri type 1 with extensive involvement of the spinal cord and BRAF V600E mutation.

Authors:  Ivan Fernandez-Vega; Jennifer Quirk; Fiona L Norwood; Naomi A Sibtain; Ross Laxton; Istvan Bodi
Journal:  Pathol Oncol Res       Date:  2013-12-19       Impact factor: 3.201

3.  Leptomeningeal gliomatosis as the initial presentation of gliomatosis cerebri.

Authors:  Matthew K Knox; Cynthia Ménard; Warren P Mason
Journal:  J Neurooncol       Date:  2010-02-10       Impact factor: 4.130

4.  Incidence and survival of gliomatosis cerebri: a population-based cancer registration study.

Authors:  Marios K Georgakis; Dimitrios Spinos; Apostolos Pourtsidis; Amanda Psyrri; Ioannis G Panourias; Spyridon Sgouros; Eleni Th Petridou
Journal:  J Neurooncol       Date:  2018-02-20       Impact factor: 4.130

5.  Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases.

Authors:  Tomoo Inoue; Toshihiro Kumabe; Masayuki Kanamori; Yukihiko Sonoda; Mika Watanabe; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2011-02-08       Impact factor: 3.042

6.  TWIST1 promotes invasion through mesenchymal change in human glioblastoma.

Authors:  Svetlana A Mikheeva; Andrei M Mikheev; Audrey Petit; Richard Beyer; Robert G Oxford; Leila Khorasani; John-Patrick Maxwell; Carlotta A Glackin; Hiroaki Wakimoto; Inés González-Herrero; Isidro Sánchez-García; John R Silber; Philip J Horner; Robert C Rostomily
Journal:  Mol Cancer       Date:  2010-07-20       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.